http://www.zibb.com/all/theme/cq/Millennium+Pharmaceuticals+Incorporated Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Tue, 14 Oct 2008 21:05:26 GMTTue, 14 Oct 2008 21:05:26 GMT608831http://www.zibb.com/all/theme/cq/Millennium+Pharmaceuticals+Incorporated http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://seekingalpha.com/article/99876-johnson-amp-johnson-q3-2008-earnings-call-transcript?source=yahooWelcome, I’m Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson and it is my pleasure this morning to review our business results for the third quarter of 2008.http://seekingalpha.com/article/99876-johnson-amp-johnson-q3-2008-earnings-call-transcript?source=yahooMillennium Pharmaceuticals IncorporatedTue, 14 Oct 2008 21:05:26 GMThttp://www.fool.com/investing/high-growth/2008/08/14/genentech-asks-roche-to-pay-up.aspxThree weeks ago, Roche bid $43.7 billion to acquire the 44% of Genentech shares that it doesn't already own. A special committee of Genentech's board of directors reviewed Roche's proposal and announced yesterday that Roche had made an offer that Genentech could refuse.http://www.fool.com/investing/high-growth/2008/08/14/genentech-asks-roche-to-pay-up.aspxMillennium Pharmaceuticals IncorporatedThu, 14 Aug 2008 19:33:15 GMThttp://www.portfolio.com/news-markets/top-5/2008/07/25/Genentech-Weighs-Roche-Bid?rss=trueFounded 30 years ago at the dawn of biotech, Genentech is a legend in an industry where companies yearn to do what it does: make billions of dollars from novel drugs while remaining true to innovationhttp://www.portfolio.com/news-markets/top-5/2008/07/25/Genentech-Weighs-Roche-Bid?rss=trueMillennium Pharmaceuticals IncorporatedFri, 25 Jul 2008 19:00:00 GMThttp://www.biospace.com/news_story.aspx?StoryID=101116&full=1CAMBRIDGE, Mass. and OSAKA, Japan, June 20 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) today announced that the U.S. Food and Drug Administration (FDA) approved VELCADE for patients with previouslyhttp://www.biospace.com/news_story.aspx?StoryID=101116&full=1Millennium Pharmaceuticals IncorporatedMon, 23 Jun 2008 12:00:00 GMThttp://www.iht.com/articles/ap/2008/06/18/business/NA-FIN-US-Biogen-Idec-Icahn.phpIcahn's chances for winning Biogen Idec campaign slim, but eventual buyout still possiblehttp://www.iht.com/articles/ap/2008/06/18/business/NA-FIN-US-Biogen-Idec-Icahn.phpMillennium Pharmaceuticals IncorporatedWed, 18 Jun 2008 21:57:56 GMThttp://www.xconomy.com/2008/04/16/a-lawsuit-for-biogen-a-suitor-for-millennium-the-suits-who-made-their-own-fate-more-life-sciences-news/First Carl Icahn stirred the Biogen Idec pot again, to nobody's surprise, then Takeda swept one of the area's mainstay companies off its feet---to everybody'shttp://www.xconomy.com/2008/04/16/a-lawsuit-for-biogen-a-suitor-for-millennium-the-suits-who-made-their-own-fate-more-life-sciences-news/Millennium Pharmaceuticals IncorporatedWed, 16 Apr 2008 14:09:32 GMThttp://www.newratings.com/main/company_headline.m?section=company&option=headline&id=1727793NEW YORK, April 11 (newratings.com) - Analysts at Robert W Baird downgrade Millennium Pharmaceuticals Inc (ticker: MLNM) from "outperform" to "neutral." The target price is set to $25. [more]http://www.newratings.com/main/company_headline.m?section=company&option=headline&id=1727793Millennium Pharmaceuticals IncorporatedFri, 11 Apr 2008 13:35:13 GMThttp://www.cnbc.com/id/24050396/?__source=yahoo|headline|quote|text|&par=yahooFollowing are the day’s biggest winners and losers. Find out why shares of Amgen and Home Depot popped while Rite Aid and First Marblehead dropped.http://www.cnbc.com/id/24050396/?__source=yahoo|headline|quote|text|&par=yahooMillennium Pharmaceuticals IncorporatedThu, 10 Apr 2008 22:45:55 GMThttp://uk.biz.yahoo.com/10042008/399/upbeat-wal-mart-lifts-wall-street.htmlUS equities overcame a wobbly start to close higher on Thursday as improved profit forecasts from Wal-Mart and a series of upgrades for technology shares helped damp fears that first-quarter corporate earnings will take a pummellinghttp://uk.biz.yahoo.com/10042008/399/upbeat-wal-mart-lifts-wall-street.htmlMillennium Pharmaceuticals IncorporatedThu, 10 Apr 2008 16:15:20 GMThttp://www.pharmaceutical-business-review.com/article_news.asp?guid=27F923DE-6415-4A69-B8D7-E8C6F6FF8A00Takeda Pharmaceutical Company and Millennium Pharmaceuticals have entered into a definitive agreement pursuant to which Takeda will acquire Millennium for approximately $8.8 billion through a cash tender offer of $25 per share.http://www.pharmaceutical-business-review.com/article_news.asp?guid=27F923DE-6415-4A69-B8D7-E8C6F6FF8A00Millennium Pharmaceuticals IncorporatedThu, 10 Apr 2008 14:25:00 GMThttp://www.bloggingstocks.com/2008/04/10/cephalon-ceph-gets-a-boost-from-millennium-mlnm-buyout/Filed under: Deals, Good news, Options, Technicalhttp://www.bloggingstocks.com/2008/04/10/cephalon-ceph-gets-a-boost-from-millennium-mlnm-buyout/Millennium Pharmaceuticals IncorporatedThu, 10 Apr 2008 13:45:00 GMThttp://www.gurufocus.com/news.php?id=21891GuruFocus tracks the stock buys, sells and commentaries of stock investment gurus such as Warren Buffett, George Soros, the best investors.http://www.gurufocus.com/news.php?id=21891Millennium Pharmaceuticals IncorporatedFri, 08 Feb 2008 05:54:12 GMThttp://www.boston.com/business/healthcare/articles/2008/01/24/outgoing_perkinelmer_chief_sets_a_new_course/PerkinElmer Inc. chief executive Gregory L. Summe plans to launch a new career in private equity when he steps down as the chief executive of the Waltham life sciences company next month.http://www.boston.com/business/healthcare/articles/2008/01/24/outgoing_perkinelmer_chief_sets_a_new_course/Millennium Pharmaceuticals IncorporatedThu, 24 Jan 2008 07:34:35 GMThttp://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/12-03-2007/0004715835&EDATE=millennium.com. (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ) The presentation will be delivered by Millennium senior management as well as clinical investigators and will include an overview of clinical trial data for VELCADE(R) (bortezomib) for Injection.http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/12-03-2007/0004715835&EDATE=Millennium Pharmaceuticals IncorporatedMon, 03 Dec 2007 21:27:00 GMThttp://www.businesswire.com/portal/site/home/index.jsp?viewID=news_view&beanID=202776713&newsId=20071002005935&ndmHsc=v2*A1191322800000*B1191360913000*DgroupByDate*J1*N1000837&epi-content=GENERICBusiness Wire is the leading source for full-text breaking news and press releases, multimedia and regulatory filings for companies and groups throughout the world.http://www.businesswire.com/portal/site/home/index.jsp?viewID=news_view&beanID=202776713&newsId=20071002005935&ndmHsc=v2*A1191322800000*B1191360913000*DgroupByDate*J1*N1000837&epi-content=GENERICMillennium Pharmaceuticals IncorporatedTue, 02 Oct 2007 14:42:01 GMThttp://www.icis.com/Articles/2005/04/01/664745/jobs-and-people.htmlhas been appointed vice president of oncology and global clinical development at Schering-Plough Research Institute. Most recently, Dr. Arbuck was vice president and global head of the oncology therapeutic area at Aventis Pharmaceuticals. Abbie Celnikerhttp://www.icis.com/Articles/2005/04/01/664745/jobs-and-people.htmlMillennium Pharmaceuticals IncorporatedFri, 01 Apr 2005 20:47:32 GMThttp://www.dddmag.com/news-Takeda-Acquires-Millennium-Pharmaceuticals-for-8.aspxTakeda Pharmaceutical Company will acquire Millennium Pharmaceuticals, developer of VELCADE (bortezomib) for approximately $8.8 billion.http://www.dddmag.com/news-Takeda-Acquires-Millennium-Pharmaceuticals-for-8.aspxMillennium Pharmaceuticals Incorporatedhttp://www.smalltimes.com/articles/stm_print_screen.cfm?ARTICLE_ID=267635SAN DIEGO, Nov. 5, 2001 -- A Boston University law professor, addressing a microtechnology conference here last week, displayed a series of mock magazine covers, including ones announcing the discovery of genes for disposition to crime ("Bad Boy"), homosexuality, even infidelity.http://www.smalltimes.com/articles/stm_print_screen.cfm?ARTICLE_ID=267635Millennium Pharmaceuticals Incorporatedhttp://topics.nytimes.com/top/news/business/companies/curagen-corporation/index.htmlCuraGen, which uses genetic information to develop treatments for disease, say they will cut about 110 jobs in Connecticut or 30 percent of work force, to focus on drugs in most advanced stages of developmenthttp://topics.nytimes.com/top/news/business/companies/curagen-corporation/index.htmlMillennium Pharmaceuticals Incorporatedhttp://www.smartbrief.com/news/companyData.jsp?companyId=19575Business Wire | 8 days 16 hours 34 minutes ago Archemix Corp., a privately-held biotechnology company working to develop aptamer-based therapeutics, announced today that it has initiated a Phase 2b clinical trial of its novel anti-von Willebrand Factor (vWF) aptamer, ARC1779.http://www.smartbrief.com/news/companyData.jsp?companyId=19575Millennium Pharmaceuticals Incorporatedhttp://www.entrepreneur.com/tradejournals/article/187588148.htmlMillennium Pharmaceuticals, Inc. (Cambridge, MA) has patented antibodies or antigen-binding fragments thereof which binds the chemokine mammalian TECK and inhibit binding of the chemokine to mammalian GPR-9-6.http://www.entrepreneur.com/tradejournals/article/187588148.htmlMillennium Pharmaceuticals Incorporatedhttp://www.janssenpharmaceutica.be/news_headlines11_E.aspScience Magazine publishes the survey results in its October issue. Beerse, October 8, 2002 – Science Magazine, the leading journal for scientists, conducted a survey among its own readers asking which companies made the best employers and why.http://www.janssenpharmaceutica.be/news_headlines11_E.aspMillennium Pharmaceuticals Incorporatedhttp://www.holdrs.com/holdrs/main/index.asp?Action=Article&Description=&Image=&newsid={86793B0E-6142-4E55-8475-BC8049B033BD}&symb=IMGN&sid=6291"The study findings to date are highly encouraging as IMGN901, used as a single agent, demonstrated biological activity in patients whose multiple myeloma has relapsed after treatment with several well-accepted therapies," commented Asher Chanan-Khan, MD, of the Roswell Park Cancer Institute.http://www.holdrs.com/holdrs/main/index.asp?Action=Article&Description=&Image=&newsid={86793B0E-6142-4E55-8475-BC8049B033BD}&symb=IMGN&sid=6291Millennium Pharmaceuticals Incorporatedhttp://www.intel.com/capital/news/releases/060821.htmWaltham, MA August 21, 2006 - CircleLending, Inc., the pioneer in managing private mortgages and loans between relatives and friends, today announced that it has secured $10 million in venture capital funding.http://www.intel.com/capital/news/releases/060821.htmMillennium Pharmaceuticals Incorporatedhttp://www.aviron.com/press/printstory.asp?reqid=980690&yr=2007GAITHERSBURG, Md., April 2 /PRNewswire-FirstCall/ -- MedImmune, Inc. (Nasdaq: MEDI) today announced that it has promoted three senior leaders within its research and development (RD) and medical organizations.http://www.aviron.com/press/printstory.asp?reqid=980690&yr=2007Millennium Pharmaceuticals Incorporated